Skip to content


    DEA Class; OTC, Rx

    Common Brand Names; Dramamine

    • Antiemetic Agents; 
    • Antihistamines, 1st Generation; 
    • Antiemetics, Antihistamine

    Ethanolamine H1 antagonist containing diphenhydramine and 8-chloro-theophylline; pharmacological effects principally result from diphenhydramine moiety, has CNS depressant, anticholinergic, antiemetic, antihistamine, and local anesthetic effects

    Antiemetic action may result from inhibiting vestibular stimulation, and inhibiting acetylcholine

    Indicated for the management of

    • Prevention of Motion Sickness
    • Meniere’s Disease (Off-label)

    Documented hypersensitivity to dimenhydrinate or diphenhydramine

    Lower respiratory disease, eg, asthma (controversial)

    Preemies and neonates

    Nursing women

    • Paradoxical CNS stimulation (children and occasionally in adults)
    • CNS depression
    • Drowsiness
    • Sedation ranging from mild drowsiness to deep sleep (most frequent)
    • Dizziness
    • Lassitude
    • Disturbed coordination
    • Muscular weakness
    • Restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures is less common
    • Epigastric distress
    • Anorexia
    • Nausea
    • Vomiting
    • Diarrhea
    • Constipation
    • Cholestasis, hepatitis, hepatic failure, hepatic function abnormality, jaundice is rare
    • Eczema, pruritus, inflammation, papular rash, erythema on exposed skin may occur with topical formulation
    • Tachycardia, palpitation ECG changes (eg, widened QRS)
    • Arrhythmias (eg, extrasystole, heart block)
    • Hypotension
    • Hypertension
    • Dizziness, sedation, and hypotension may occur in geriatric patients
    • Dryness of mouth, nose, and throat
    • Dysuria
    • Urinary retention
    • Impotence
    • Vertigo
    • Visual disturbances
    • Blurred vision
    • Diplopia; tinnitus
    • Acute labyrinthitis
    • Insomnia
    • Tremors
    • Nervousness
    • Irritability
    • Facial dyskinesia
    • Tightness of the chest
    • Thickening of bronchial secretions
    • Wheezing
    • Nasal stuffiness
    • Sweating
    • Chills

    May impair ability to drive or operate heavy machinery

    May mask early signs of ototoxicity if given concomitantly with ototoxic drugs (eg, aminoglycosides)

    Patients with seizures, angle-closure glaucoma, enlargement of prostate gland, asthma, emphysema, acute hepatic insufficiency

    Pregnancy Category: B

    Lactation: Crosses into breast milk, discontinue drug or do not nurse


    50-100 mg PO/IV/IM q4-6hr PRN, 30 minutes before exposure to motion; not to exceed 400 mg/day


    50-100 mg PO/IV/IM q4-6hr PRN, 30 minutes before exposure to motion; not to exceed 400 mg/day


    General dose: 1.25 mg/kg or 37.5 mg/sq.meter IV/IM q6hr; not exceed 300 mg/day  

    2-6 years old: 12.5-25 mg PO q6-8hr; no more than 75 mg/day

    6-12 years old: 12.5-25 mg PO q6-8hr; no more than 150 mg/day

    >12 years old: Same as adult dosing


    injectable solution

    • 50mg/mL


    • 50mg

    tablet, chewable

    • 50mg